| Please check with your doctor or call 1-855-HCH-HOPE (424-4673) to find out if you qualify for any of these studies.
|
Trial #
|
Trial Sub-type
|
Title
|
|
C05013
Millennium, Inc.
|
Patients with previously-untreated non-GCB DLBCL.
|
An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma
|
|
OMB110918
GSK
|
Small lymphocytic, lymphoplasmacytic, marginal zone lymphoma, and follicular
lymphoma (FL); grades 1, 2 and 3A
|
Clinical trial of OfatuMumab and bendamustine in Patients with indolent NHL that is refractory to other treatment A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment
|
|
ECOG E1411
|
Mantle Cell Lymphoma
Front - line Patients ³ 60
|
Intergroup Randomized Phase II Four Arm Study In Patients ³ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
|
|
